Laura Maria Fogliatto

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

John P. Leonard, Marek Trněný, Koji Izutsu et al. · Journal of Clinical Oncology · 2019 · 421 citations · Full text

Medicine, Immunology, Oncology +15

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Philippe Armand, Scott J. Rodig, Catherine Thiéblemont et al. · Journal of Clinical Oncology · 2019 · 259 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 258 citations

Medicine, Oncology, Pharmacology +15

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Drew J. Winston, Kathleen M. Mullane, Oliver A. Cornely et al. · The Lancet · 2018 · 96 citations

Veterinary Medicine, Immunology, Infectious Diseases +16

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170

Pier Luigi Zinzani, Catherine Thiéblemont, Krimo Bouabdallah et al. · Blood · 2023 · 60 citations · Full text

Medicine, Oncology, Pharmacotherapy +15